Evidence map›Paper›PMID 34503096›Full record

ArticleCancers2021

External Validation of a Nomogram to Predict Survival and Benefit of Concurrent Chemoradiation for Stage II Nasopharyngeal Carcinoma.

Pui-Lam Yip, Shing-Fung Lee, Cheuk-Wai Horace Choi, Po-Chung Sunny Chan, Ka-Wai Alice Cheung, Chung-Hang James Chow, Ka-Man Cheung, Wing-Yu Jessica Lai, Ho-Fun Victor Lee, Ka-On Lam and 9 more

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Concurrent chemoradiotherapy versus radiotherapy alone for stage II nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Pui-Lam YipDepartment of Clinical Oncology, Tuen Mun Hospital, Hospital Authority, Hong Kong, China.
Shing-Fung LeeDepartment of Clinical Oncology, Tuen Mun Hospital, Hospital Authority, Hong Kong, China.
Cheuk-Wai Horace ChoiDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, China.
Po-Chung Sunny ChanDepartment of Clinical Oncology, Tuen Mun Hospital, Hospital Authority, Hong Kong, China.
Ka-Wai Alice CheungDepartment of Clinical Oncology, Tuen Mun Hospital, Hospital Authority, Hong Kong, China.
Chung-Hang James ChowDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hospital Authority, Hong Kong, China.
Ka-Man CheungDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hospital Authority, Hong Kong, China.
Wing-Yu Jessica LaiDepartment of Oncology, Princess Margaret Hospital, Hospital Authority, Hong Kong, China.
Ho-Fun Victor LeeDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, China.
Ka-On LamDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, China.
Chi-Leung ChiangDepartment of Clinical Oncology, Tuen Mun Hospital, Hospital Authority, Hong Kong, China.ORCID 0000-0002-9836-6478
Chun-Yin Edwin WongDepartment of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hospital Authority, Hong Kong, China.
Ming-Chun Darren PoonDepartment of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China.
Macy TongDepartment of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China.
Kwok-Hung AuDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hospital Authority, Hong Kong, China.
Wai-Tong NgDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, China.ORCID 0000-0001-6696-3000
Kai-Cheong Roger NganDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, China.
Wing-Mui Anne LeeDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, China.ORCID 0000-0003-2972-0231
Yuk Stewart TungDepartment of Clinical Oncology, Tuen Mun Hospital, Hospital Authority, Hong Kong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A nomogram was recently published by Sun et al. to predict overall survival (OS) and the additional benefit of concurrent chemoradiation (CCRT) vs. radiotherapy (RT) alone, in stage II NPC treated with conventional RT. We aimed to assess the predictors of OS and to externally validate the nomogram in the IMRT era. We analyzed stage II NPC patients treated with definitive RT alone or CCRT between 2001 and 2011 under the territory-wide Hong Kong NPC Study Group 1301 study. Clinical parameters were studied using the Cox proportional hazards model to estimate OS. The nomogram by Sun et al. was applied with 1000 times bootstrap resampling to calculate the concordance index, and we compared the nomogram predicted and observed 5-year OS. There were 482 patients included. The 5-year OS was 89.0%. In the multivariable analysis, an age > 45 years was the only significant predictor of OS (HR, 1.98; 95%CI, 1.15-3.44). Other clinical parameters were insignificant, including the use of CCRT (HR, 0.99; 95%CI, 0.62-1.58). The nomogram yielded a concordance index of 0.55 (95% CI, 0.49-0.62) which lacked clinically meaningful discriminative power. The nomogram proposed by Sun et al. should be interpreted with caution when applied to stage II NPC patients in the IMRT era. The benefit of CCRT remained controversial.

Indexed as

chemotherapynasopharyngeal carcinomanomogramradiotherapysurvival

Identifiers

PMID34503096
PMCPMC8428339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.